RT - European Journal of Gynaecological Oncology ID - 10.22514/ejgo.2023.088 T1 - Inhibition of MARK2 inhibits ovarian cancer cell proliferation by regulating PI3K/AKT/p53 axis A1 - Weijie Xiong A1 - Hongyu Xu A1 - Yuntao Wang A1 - Ying Wang A1 - Lang He K1 - Ovarian cancer (OC); Microtubule affinity regulated kinase 2 (MARK2); Apoptosis; glucose metabolism; PI3K/AKT/p53 YR - 2023 SP - 132 AB -
Ovarian cancer (OC) is the 3rd most common type of the gynecological malignancy. Although current treatment strategies have greatly improved, there is still a need to develop new biomarkers for OC diagnosis and treatment. Microtubule affinity regulated kinase 2 (MARK2) is a kinase involved in the progression of multiple tumors. However, whether abnormal expression of MARK2 is associated with OC progression needs further analysis. We here revealed its role in OC. We found high expression of MARK2 in OC. Knockdown of MARK2 inhibited proliferation of OC cells, stimulated apoptosis of OC cells, and restrained glucose metabolism of OC cells. Furthermore, MARK2 regulated phosphatidylinositol 3-kinase/PKB (protein kinase B)/tumor suppressor protein 53 (PI3K/AKT/p53) axis in OC, therefore affecting the progression of OC. In summary, MARK2 knockdown suppressed cell proliferation by regulating PI3K/AKT/p53 axis.